Yuan Yanhan, Chen Jiayi, Liu Tianyu, Chen Juanjuan, Zhang Feng, Shi Zhe, Zhang Jinping
Department of Pediatrics, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
College of Food Science and Technology, Shanghai Ocean University, Shanghai, China.
Front Nutr. 2025 Apr 8;12:1581242. doi: 10.3389/fnut.2025.1581242. eCollection 2025.
To assess whether AB-GG supplementation has a treatment effect on the neonatal jaundice of infants receiving phototherapy.
In this study, 11 and 10 neonates in experimental and control groups were recruited, respectively (upon the follow-up of experimental groups at 7-14 days after discharge, stool frequency was decreased commonly. Therefore, this study was prematurely terminated). After 12 h of phototherapy, researchers recorded clinical information and measured transcutaneous bilirubin (TCB). Fresh fecal samples were collected at seven specific time points: before phototherapy (A), after 12 (B), 24 (C) and 36 h (D) of phototherapy, as well as 10 (D10), 20 (D20) and 30 days (D30) after delivery.
A tendency toward fewer blue light sessions and shorter time of hospitalization was shown in experimental groups, but this exhibited no statistical significance ( > 0.05). Compared with the experimental groups, phototherapy significantly reduced the alpha (α) diversity of intestinal flora in the control groups. However, phototherapy had no significant effect on beta (β) diversity between experimental and control groups. This study also observed that the metabolic composition structures of both groups underwent changes before and after phototherapy. However, no significantly differential metabolites were identified when the groups were compared at different time points.
supplementation was shown to mitigate intestinal dysbiosis in jaundiced neonates, which thereby facilitated a more rapid recovery of gut microbiota depleted by phototherapy.
It was registered with the Chinese Clinical Trial Registry (Registration No.: ChiCTR2000036013).
评估补充AB-GG对接受光疗的婴儿新生儿黄疸是否有治疗效果。
本研究分别招募了11名和10名实验组和对照组的新生儿(在实验组出院后7 - 14天进行随访时,排便频率普遍下降。因此,本研究提前终止)。光疗12小时后,研究人员记录临床信息并测量经皮胆红素(TCB)。在七个特定时间点收集新鲜粪便样本:光疗前(A)、光疗12(B)、24(C)和36小时(D),以及出生后10(D10)、20(D20)和30天(D30)。
实验组显示出蓝光照射次数减少和住院时间缩短的趋势,但无统计学意义(>0.05)。与实验组相比,光疗显著降低了对照组肠道菌群的α多样性。然而,光疗对实验组和对照组之间的β多样性没有显著影响。本研究还观察到两组的代谢组成结构在光疗前后均发生了变化。然而,在不同时间点比较两组时,未发现显著差异的代谢物。
补充AB-GG可减轻黄疸新生儿的肠道菌群失调,从而促进因光疗而耗竭的肠道微生物群更快恢复。
已在中国临床试验注册中心注册(注册号:ChiCTR2000036013)。